FDA Alignment And HLHS Trial Will Enable Market Access

Published
15 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$8.39
90.1% undervalued intrinsic discount
15 Aug
US$0.83
Loading
1Y
-63.0%
7D
21.6%

Author's Valuation

US$8.4

90.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on15 Aug 25

Longeveron's valuation outlook has strengthened, with a sharp drop in its forward P/E multiple and improved net profit margin indicating better profitability and a more attractive risk-reward profile, though the consensus analyst price target remains unchanged at $8.39. What's in the News Longeveron completed a $17.5 million follow-on equity offering, issuing 5.62 million shares of Class A common stock, 14.71 million warrants, and 265,000 pre-funded warrants at $0.85 per security.

Shared on01 May 25
Fair value Decreased 5.63%

Shared on24 Apr 25